Table 2.
Associations between genetically proxied inhibition of HMGCR, NPC1L1, or PCSK9 and erectile dysfunction.
| Method | nSNPs | Beta | SE | OR (95%CI) | P value |
|---|---|---|---|---|---|
| HMGCR | |||||
| Inverse variance weighted | 7 | 0.24 | 0.11 | 1.27 (1.03–1.57) | 2.8e−02 |
| MR Egger | 7 | 0.18 | 0.84 | 1.20 (0.23–6.25) | 0.84 |
| Weighted median | 7 | 0.18 | 0.21 | 1.19 (0.79–1.80) | 0.40 |
| NPC1L1 | |||||
| Inverse variance weighted | 3 | − 0.34 | 0.34 | 0.71 (0.37–1.38) | 0.31 |
| MR Egger | 3 | 3.27 | 2.53 | 26.32 (0.19–3742.92) | 0.42 |
| Weighted median | 3 | − 0.13 | 0.39 | 0.87 (0.41–1.87) | 0.73 |
| PCSK9 | |||||
| Inverse variance weighted | 12 | − 0.12 | 0.12 | 0.88 (0.69–1.13) | 0.32 |
| MR Egger | 12 | − 0.25 | 0.20 | 0.78 (0.52–1.16) | 0.24 |
| Weighted median | 12 | − 0.17 | 0.14 | 0.84 (0.64–1.11) | 0.22 |